Data on the capacity of hemodialysis to remove dolutegravir (DTG) from plasma in patients with end-stage renal disease (ESRD) on hemodialysis (HD) are lacking. If DTG was removed from plasma by HD, it would be possible to have subtherapeutic drug concentrations at the end of HD sessions.
The prevalence of chronic renal disease and end-stage renal disease (ESRD) is increasing in the HIV-positive population. This means that an increasing number of HIV-infected patients will need renal replacement therapy.However, little is known about DTG removal from plasma by HD in patients with ESRD. Objective: to evaluate the effect of HD on DTG clearance as well as on DTG plasma concentrations at steady state in HIV-infected patients with ESRD undergoing HD.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
5
Dolutegravir 50mg/day per 5 days
Germans Trias i Pujol Hospital
Badalona, Barcelona, Spain
hemodialysis extraction ratio of dolutegravir
Time frame: Day 5
hemodialysis clearance of dolutegravir
Time frame: Day 5
percentage of patients presenting adverse events related to dolutegravir
Time frame: From Baseline to day 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.